Success both in rescue and scientific research: comparison of medical papers published by Chinese in two epidemics
Adverse Drug Reactions Journal Agency, Beijing 100053, China; Liver Disease Center, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China; Department of Pharmacy, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
Abstract：Facing the unprecedented epidemic situation of novel coronavirus pneumonia (COVID-19), medical workers in China have not only successfully controlled the spread of the epidemic in Chinese mainland in just 4 months, but also have made great achievements in scientific research on COVID-19. In the past 4 months, a total of 1-033 English papers about COVID-19 written by Chinese scholars have been published and included in PubMed database, which is 6.6 times the number of articles published in 2003. The proportion of papers published by authors in Chinese mainland has increased from 48.7% （76/156） during the SARS epidemic in 2003 to 84.8% （876/1-033） with 4 months in 2020. The papers were also published significantly earlier than before. Chinese researchers identified the novel coronavirus that caused the outbreak less than 1 month after the COVID-19 outbreak (on January 7, 2020) and reported it to the WHO. They also published articles on the genetic sequence and transmission dynamics of the virus and clinical characteristics of COVID-19 patients in that month. China pays more attention to drug safety of patients. The proportion of English and Chinese literature published by pharmaceutical authors increased from 0 and 0.2% (10/4-023) in 2003 to 2.3% (24/1-032) and 9.3% (215/2-317) from January to April in 2020, respectively. China has not only become a model for the world in epidemic control, but also made important contributions to the relevant academic research.
蔡晧东，王育琴. 施救与科研双告捷：两次疫情中我国医学论文发表情况对比[J]. 药物不良反应杂志, 2020, 22(6): 329-332.
Cai Haodong, Wang Yuqin. Success both in rescue and scientific research: comparison of medical papers published by Chinese in two epidemics. Adverse Drug Reactions Journal, 2020, 22(6): 329-332.
